All In Biotech

Drug Trial Radar · NCT05969275

Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock

Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Multi-Center, Double Blind, Phase II Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

296

Planned (sponsor's estimate)

Start

Feb 14, 2024

Primary completion

Sep 30, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); Stem Cell Network; Canadian Critical Care Trials Group; Technische Universität Dresden
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated MSCs in patients with septic shock. The Cellular Immunotherapy for Septic Shock Phase I (CISS) trial established that MSCs appear safe and that a randomized controlled trial (RCT) is feasible. Based on these data, the investigators have planned a phase II RCT (UC-CISS II) at several Canadian academic centres which will evaluate intermediate measures of clinical efficacy (primary outcome), as well as biomarkers, safety, clinical outcome measures, and a health economic analysis (secondary outcomes).

Conditions

  • Septic Shock
  • Sepsis
  • Pathologic Processes
  • Shock
  • Systemic Inflammatory Response Syndrome
  • Inflammation
  • Infections

Interventions

  • Allogeneic umbilical cord-derived human mesenchymal stromal cellsBiological

    Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells

  • PlaceboOther

    Intravenous infusion of placebo, with excipients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Days free from mechanical ventilation and/or vasopressors and/or renal replacement therapyTime frame: Through to 28 days post-randomization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Ottawa Hospital (General Campus)

    Ottawa, Ontario, Canada · Recruiting

  • The Ottawa Hospital (Civic Campus)

    Ottawa, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.